Table 2.

Adverse events experienced during treatment

Adverse event	Number of cases
Renal
Hyperkalemia > 5.5 mEq/dL†	1
Rise in creatinine ≥ 0.3mg/dL	1
Hematologic
Decrease in hemoglobin ≥ 1.0g/dL	2
Anemia requiring ESA	0
Fatigue	1
Dizziness/Lightheadedness	1
Insomnia/Agitation/Anxiety††	3
Infection†††	2
Photosensitivity	2
Rash	1
Vitiligo	1
Palpitations	1
Xerosis	1
Xerophthalmia	1
Nausea	1
Headache	1
Hypoglycemia	1
Hypokalemia	1

Legend: Eight of twelve patients experienced at least one adverse event. The frequency count of each adverse event is listed above.

^†Patient required emergency room evaluation and treatment with intravenous hydration and intravenous calcium despite absence of electrocardiogram changes. Hyperkalemia was then managed with low potassium diet, oral bumetanide daily and twice weekly sodium polysterene.

^††One patient experienced severe worsening of anxiety requiring cessation of sofosbuvir and ribavirin at week 10 of 12.

^†††Infections included one urinary tract infection and pneumonia. Both were treated with antibiotics and resolved without complications.

Abbreviations: ESA = erythropoietin stimulating agent